Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
cosentyx
Press Release
Sep 14, 2018
Latest Biologic Launch in Psoriasis, UCB's Cimzia, Having a Tough Time Getting Traction, But Developing a Presence in Dermatology May Lay Foundation for Bimekizumab in the Future
Janssen's Tremfya continues to post gains, but may soon face competition as Sun Dermatology readies for the launch of Ilumya (tildrakizumab), the second IL-23 inhibitor to be introduced in the U.S. market, according to a new report from Spherix Global Insights
Read More
Press Release
Sep 6, 2018
Ankylosing Spondylitis Market Largely Dominated by TNF-Inhibitors, Though Novartis' Cosentyx Enjoyed Significant Year Over Year Gains and a Growing Percent of Rheumatologists Report Off-Label Use of Pfizer's Xeljanz
With no current FDA approved biologics for the treatment of non-radiographic axial spondyloarthropathy, overall penetration of biologics/JAKs is significantly lower than for ankylosing spondylitis; however, when these agents are prescribed, brand usage closely mirrors the ankylosing spondylitis indication, according to a new publication by Spherix Global Insights
Read More
First
Prev
1
Next
Last